We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

By LabMedica International staff writers
Posted on 24 May 2024
Print article
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability among young adults. The urgent need for improved treatments has led to extensive research into various viruses associated with MS, with the Epstein-Barr Virus (EBV) emerging as a significant risk factor for the disease. It remains unclear why certain individuals with MS exhibit an abnormal immune response to EBV, which typically causes no symptoms in most people. Now, a novel blood test has been developed that measures the immune response to EBV, providing new avenues for basic research into EBV's role in MS and potential applications in clinical trials aimed at targeting the virus.

Researchers at Trinity College Dublin (Dublin, Ireland) conducted studies measuring the immune response of MS patients to EBNA-1, a component of EBV that resembles the myelin sheath of nerves, which is the primary target of the immune attack in MS. They discovered that this immune response is heightened in MS patients compared to individuals with epilepsy or healthy controls. The research also indicated that this response is influenced by existing MS medications that suppress the immune system but do not specifically target the virus. They noted that the immune response to EBNA-1 was reduced in MS patients who are on B-cell depleting medications, aligning with levels seen in healthy controls, compared to those not on any medication.

B-cell depleting therapies are known to decrease MS activity, though the precise mechanism is not fully understood. It is hypothesized that these medications may reduce EBV levels, which can reside dormant within B cells. The study did not confirm this hypothesis but did illustrate that immune responses to EBV in MS patients treated with these medications are comparable to those in healthy individuals. The researchers argue that this underscores the potential benefits of selectively targeting EBV rather than broadly suppressing all B cells, given B cells' crucial role in fighting infections and the risks of broader immune suppression. This research is groundbreaking as it is the first to use standard hospital laboratory equipment to assess the immune response to EBNA-1 using whole blood samples. This method contrasts with previous studies that required extensive sample preparation in specialized research labs.

The simplicity of the new test demonstrates its potential for broader application and scalability without the need for specialized equipment or additional staff. This development is significant as it enables the standard blood test, processed in a hospital lab, to provide vital insights into the immune system's response to EBNA-1, which is central to MS's pathogenesis. The scalability of this test, based on existing diagnostic techniques, opens up possibilities for further basic research into EBV's biology in relation to MS. Moreover, this test could be used in clinical trials targeting the virus, allowing for the direct measurement of the immune response to potential antiviral treatments rather than solely focusing on MS-related outcomes.

“In the short term the benefit of this research is likely to be for the research community in MS,” said Dr. Hugh Kearney, Neurologist, School of Medicine, Trinity College. “We believe the approach adopted in this test that uses whole blood samples on a robust hospital-based platform will facilitate adoption in other centers and also replication of the results with a view towards validation. In the medium term, if validated, then this would be of benefit to researchers involved in clinical trials in MS. Long term benefits will be for people with MS, who live with a chronic neurological illness as new treatments tested in clinical trials have the potential to reduce the burden of this potentially disabling disease.”

Related Links:
Trinity College Dublin

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.